https://doi.org/10.55788/5a83a465
“Istaroxime was designed to improve both systolic contraction and diastolic relaxation.” clarified Prof. Marco Metra (University of Brescia, Italy) [1]. Istaroxime is a positive inotropic agent that elevates intracellular sodium levels by inhibiting sacrolemma sodium/potassium adeonosine triphosphatase and enhances the heart’s relaxation phase by activating Sarco/endoplasmic Reticulum Calcium ATPase, isotype 2a (SERCA2a). The current, randomised, double-blind, placebo-controlled, phase 2 SEISMiC study (NCT04325035) assessed the efficacy and safety of 24-hour infusion of istaroxime in 60 participants with Society for Cardiovascular Angiography and Interventions (SCAI) stage B cardiogenic shock (SBP <90 mmHg, or MAP <60 mmHg, or >30 mm drop from baseline). Focussing on the systolic contraction effect of istaroxime, the primary endpoint was the change in the Area Under Curve (AUC) for SBP over 6 hours.
Participants on istaroxime (n=30) had a significantly larger increase in SBP AUC over 6 hours compared with placebo (44.6 vs 28.1 mmHg/hr; P=0.017). After withdrawal from istaroxime, the SBP of patients who had received this agent returned to the level of placebo-receivers. The investigators did not observe differences in heart rate alterations between participants in the experimental arm and those in the placebo arm nor was there any evidence of an adverse effect of istaroxime on renal function. Furthermore, echocardiographic parameters displayed a benefit of istaroxime over placebo: the cardiac index change from baseline was 0.16 versus -0.057 (P=0.016); left ventricular end-diastolic volume was -6.51 mL versus 5.64 mL (P=0.034); and left atrium area was -1.82 cm2 versus 0.04 cm2 (P=0.008), respectively.
In each study group, 6 serious adverse events were reported. Adverse drug reactions occurred in 52% of the participants, mostly being gastrointestinal complaints (31%) or infusion site pain (14%). Notably, serious adverse events occurred only in participants receiving 1.5 μg/kg/min but not in participants receiving 1.0 μg/kg/min, while the haemodynamic effects of istaroxime were similar.
“This study supports the continuance of the development of istaroxime as a potential treatment for both acute heart failure and cardiogenic shock,” concluded Prof. Metra.
- Metra M, et al. The safety and efficacy of istaroxime for PreCardiogenic Shock. LBT Pharmacological treatment II, Heart Failure 2022, 21–24 May, Madrid, Spain.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« SERENADE: Macitentan fails in HFpEF plus PAH Next Article
DAPA-VO2: Rapid effect of dapagliflozin on peak VO2 in stable HFrEF »
« SERENADE: Macitentan fails in HFpEF plus PAH Next Article
DAPA-VO2: Rapid effect of dapagliflozin on peak VO2 in stable HFrEF »
Table of Contents: HFA 2022
Featured articles
Phase 3 and 4 Trials
GALACTIC-HF: Omecamtiv mecarbil as option for HFrEF patients with low SBP
HELIOS-A: Vutrisiran meets exploratory endpoints
Patiromer helps HFrEF patients to optimise RAAS inhibitors without hyperkalaemia
FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status
DAPA-VO2: Rapid effect of dapagliflozin on peak VO2 in stable HFrEF
Phase 1/2 Trials
Significant improvement in BP from istaroxime, a novel non-adrenergic agent
SERENADE: Macitentan fails in HFpEF plus PAH
Combination of filgrastim and dutogliptin appears safe in STEMI
Therapeutic Devices
Cardiac contractility modulation therapy promising for patients with HFpEF
REBALANCE-HF: Encouraging observations for splanchnic nerve ablation in HFpEF
Updates on SGLT2 Inhibitors
DAPA-HF: Dapagliflozin is safe and efficacious in frail patients
EMPEROR-Preserved: Empagliflozin stable across age groups
EMPULSE: Empagliflozin delivers rapid and clinically meaningful decongestion
Dapagliflozin performs consistently across LVEF in HF
Miscellaneous Topics
Cardiac wasting relevant for clinical outcomes in cancer
Urocortin-2 a potential treatment target for HFpEF
Should ATTR-CM be added to the differential diagnosis of patients with HF?
Delayed initiation of novel GDMTs associated with adverse outcomes in HF patients
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy